skf 81297 Search Results


skf 81297  (TargetMol)
N/A
   Buy from Supplier
skf 81297 hydrobromide  (MedChemExpress)
N/A
SKF 81297 hydrobromide is a potent and selective dopamine D1 receptor agonist.
   Buy from Supplier
skf81297 hydrobromide  (Tocris)
95
Tocris skf81297 hydrobromide
a , Experimental schematic. Male mice were injected in vSub with an AAV-dLight-1.1 (n = 15), an AAV-GRAB DA -1h (n = 15, ), an AAV-RdLight-1 (n = 6, ) or with a control AAV-GFP (n = 8) and implanted with optical fibers before recording during EPM testing. b , Representative traces during EPM exploration for a dLight-1.1 (top) and control GFP (bottom) animal. c , Spatially averaged fluorescence signal in the EPM for all dLight-1.1 (top-left) and all GFP (bottom-right) mice. d , Average dLight-1.1 signal during entries to (left) and exits from (right) the open arm (OA, blue) or closed arm as a control (CA, red). Only traces when the mouse did a complete closed arm to center (Ce) to open/closed arm are used for averaging. e , Average area under the curve (AUC) by EPM compartment for dLight-1.1 (left) and GFP (right) mice. LMM-ANOVA: compartment F 2,80 = 49.82 p < 0.0001, sensor F 3,40 = 1.70 p = 0.1822, compartment x sensor F 6,80 = 5.1529 p = 0.0002; followed by FDR-adjusted post-hoc tests. f , Experimental schematic for slice electrophysiological recordings from vCA1/vSub D1 or D2 pyramidal neurons identified in D1-Cre or D2-Cre x fl/fl eGFP::L10a male mice. g , Representative traces of resting membrane potential before, during and after bath application of dopamine (DA, 10 µM) or of the D1 agonist <t>SKF81297</t> (SKF, 50 µM) onto D1 neurons (top), or of dopamine (DA, 10 µM) or of the D2 agonist quinpirole (Quin, 10 µM) onto D2 neurons (bottom). h , Quantification of resting membrane potential changes between baseline (BL), drug application and after wash (W). LMM-ANOVA: cell type F 1,5.8 = 0.90 p = 0.3805, agonist F 1,18.7 = 0.40 p = 0.5366, application period F 2,37.0 = 17.73 p < 0.0001, cell type x agonist F 1,18.7 = 0.51 p = 0.4851, cell type x application period F 2,37.0 = 16.39 p < 0.0001, agonist x application period F 2,37.0 = 0.23 p = 0.7972, cell type x agonist x application period F 2,37.0 = 0.02 p = 0.9821; followed by FDR-adjusted post-hoc tests. Data represented as mean ± sem.
Skf81297 Hydrobromide, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/skf+81297/SKF+81297+hydrobromide/bio_rxiv__2023__07__25__550554-110-4-6
Average 95 stars, based on 1 article reviews
skf81297 hydrobromide - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
skf 81297 hydrobromide tocris  (Tocris)
95
Tocris skf 81297 hydrobromide tocris
a , Experimental schematic. Male mice were injected in vSub with an AAV-dLight-1.1 (n = 15), an AAV-GRAB DA -1h (n = 15, ), an AAV-RdLight-1 (n = 6, ) or with a control AAV-GFP (n = 8) and implanted with optical fibers before recording during EPM testing. b , Representative traces during EPM exploration for a dLight-1.1 (top) and control GFP (bottom) animal. c , Spatially averaged fluorescence signal in the EPM for all dLight-1.1 (top-left) and all GFP (bottom-right) mice. d , Average dLight-1.1 signal during entries to (left) and exits from (right) the open arm (OA, blue) or closed arm as a control (CA, red). Only traces when the mouse did a complete closed arm to center (Ce) to open/closed arm are used for averaging. e , Average area under the curve (AUC) by EPM compartment for dLight-1.1 (left) and GFP (right) mice. LMM-ANOVA: compartment F 2,80 = 49.82 p < 0.0001, sensor F 3,40 = 1.70 p = 0.1822, compartment x sensor F 6,80 = 5.1529 p = 0.0002; followed by FDR-adjusted post-hoc tests. f , Experimental schematic for slice electrophysiological recordings from vCA1/vSub D1 or D2 pyramidal neurons identified in D1-Cre or D2-Cre x fl/fl eGFP::L10a male mice. g , Representative traces of resting membrane potential before, during and after bath application of dopamine (DA, 10 µM) or of the D1 agonist <t>SKF81297</t> (SKF, 50 µM) onto D1 neurons (top), or of dopamine (DA, 10 µM) or of the D2 agonist quinpirole (Quin, 10 µM) onto D2 neurons (bottom). h , Quantification of resting membrane potential changes between baseline (BL), drug application and after wash (W). LMM-ANOVA: cell type F 1,5.8 = 0.90 p = 0.3805, agonist F 1,18.7 = 0.40 p = 0.5366, application period F 2,37.0 = 17.73 p < 0.0001, cell type x agonist F 1,18.7 = 0.51 p = 0.4851, cell type x application period F 2,37.0 = 16.39 p < 0.0001, agonist x application period F 2,37.0 = 0.23 p = 0.7972, cell type x agonist x application period F 2,37.0 = 0.02 p = 0.9821; followed by FDR-adjusted post-hoc tests. Data represented as mean ± sem.
Skf 81297 Hydrobromide Tocris, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/skf+81297/SKF+81297+hydrobromide/pm33882305-210-54-57
Average 95 stars, based on 1 article reviews
skf 81297 hydrobromide tocris - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
skf 81297 hydrobromide  (Toronto Research Chemicals)
92
Toronto Research Chemicals skf 81297 hydrobromide
a , Experimental schematic. Male mice were injected in vSub with an AAV-dLight-1.1 (n = 15), an AAV-GRAB DA -1h (n = 15, ), an AAV-RdLight-1 (n = 6, ) or with a control AAV-GFP (n = 8) and implanted with optical fibers before recording during EPM testing. b , Representative traces during EPM exploration for a dLight-1.1 (top) and control GFP (bottom) animal. c , Spatially averaged fluorescence signal in the EPM for all dLight-1.1 (top-left) and all GFP (bottom-right) mice. d , Average dLight-1.1 signal during entries to (left) and exits from (right) the open arm (OA, blue) or closed arm as a control (CA, red). Only traces when the mouse did a complete closed arm to center (Ce) to open/closed arm are used for averaging. e , Average area under the curve (AUC) by EPM compartment for dLight-1.1 (left) and GFP (right) mice. LMM-ANOVA: compartment F 2,80 = 49.82 p < 0.0001, sensor F 3,40 = 1.70 p = 0.1822, compartment x sensor F 6,80 = 5.1529 p = 0.0002; followed by FDR-adjusted post-hoc tests. f , Experimental schematic for slice electrophysiological recordings from vCA1/vSub D1 or D2 pyramidal neurons identified in D1-Cre or D2-Cre x fl/fl eGFP::L10a male mice. g , Representative traces of resting membrane potential before, during and after bath application of dopamine (DA, 10 µM) or of the D1 agonist <t>SKF81297</t> (SKF, 50 µM) onto D1 neurons (top), or of dopamine (DA, 10 µM) or of the D2 agonist quinpirole (Quin, 10 µM) onto D2 neurons (bottom). h , Quantification of resting membrane potential changes between baseline (BL), drug application and after wash (W). LMM-ANOVA: cell type F 1,5.8 = 0.90 p = 0.3805, agonist F 1,18.7 = 0.40 p = 0.5366, application period F 2,37.0 = 17.73 p < 0.0001, cell type x agonist F 1,18.7 = 0.51 p = 0.4851, cell type x application period F 2,37.0 = 16.39 p < 0.0001, agonist x application period F 2,37.0 = 0.23 p = 0.7972, cell type x agonist x application period F 2,37.0 = 0.02 p = 0.9821; followed by FDR-adjusted post-hoc tests. Data represented as mean ± sem.
Skf 81297 Hydrobromide, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/skf+81297/SKF+81297C/bio_rxiv__2021__01__31__429059-34-0-3
Average 92 stars, based on 1 article reviews
skf 81297 hydrobromide - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
skf 81297  (Santa Cruz Biotechnology)
85
Santa Cruz Biotechnology skf 81297
a , Experimental schematic. Male mice were injected in vSub with an AAV-dLight-1.1 (n = 15), an AAV-GRAB DA -1h (n = 15, ), an AAV-RdLight-1 (n = 6, ) or with a control AAV-GFP (n = 8) and implanted with optical fibers before recording during EPM testing. b , Representative traces during EPM exploration for a dLight-1.1 (top) and control GFP (bottom) animal. c , Spatially averaged fluorescence signal in the EPM for all dLight-1.1 (top-left) and all GFP (bottom-right) mice. d , Average dLight-1.1 signal during entries to (left) and exits from (right) the open arm (OA, blue) or closed arm as a control (CA, red). Only traces when the mouse did a complete closed arm to center (Ce) to open/closed arm are used for averaging. e , Average area under the curve (AUC) by EPM compartment for dLight-1.1 (left) and GFP (right) mice. LMM-ANOVA: compartment F 2,80 = 49.82 p < 0.0001, sensor F 3,40 = 1.70 p = 0.1822, compartment x sensor F 6,80 = 5.1529 p = 0.0002; followed by FDR-adjusted post-hoc tests. f , Experimental schematic for slice electrophysiological recordings from vCA1/vSub D1 or D2 pyramidal neurons identified in D1-Cre or D2-Cre x fl/fl eGFP::L10a male mice. g , Representative traces of resting membrane potential before, during and after bath application of dopamine (DA, 10 µM) or of the D1 agonist <t>SKF81297</t> (SKF, 50 µM) onto D1 neurons (top), or of dopamine (DA, 10 µM) or of the D2 agonist quinpirole (Quin, 10 µM) onto D2 neurons (bottom). h , Quantification of resting membrane potential changes between baseline (BL), drug application and after wash (W). LMM-ANOVA: cell type F 1,5.8 = 0.90 p = 0.3805, agonist F 1,18.7 = 0.40 p = 0.5366, application period F 2,37.0 = 17.73 p < 0.0001, cell type x agonist F 1,18.7 = 0.51 p = 0.4851, cell type x application period F 2,37.0 = 16.39 p < 0.0001, agonist x application period F 2,37.0 = 0.23 p = 0.7972, cell type x agonist x application period F 2,37.0 = 0.02 p = 0.9821; followed by FDR-adjusted post-hoc tests. Data represented as mean ± sem.
Skf 81297, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/skf+81297/SKF+81297+hydrobromide/10__1074_slash_jbc__m112__370601-63-29-30
Average 85 stars, based on 1 article reviews
skf 81297 - by Bioz Stars, 2026-10
85/100 stars
  Buy from Supplier
skf 81297  (Microm International GmbH)
90
Microm International GmbH skf 81297
a , Experimental schematic. Male mice were injected in vSub with an AAV-dLight-1.1 (n = 15), an AAV-GRAB DA -1h (n = 15, ), an AAV-RdLight-1 (n = 6, ) or with a control AAV-GFP (n = 8) and implanted with optical fibers before recording during EPM testing. b , Representative traces during EPM exploration for a dLight-1.1 (top) and control GFP (bottom) animal. c , Spatially averaged fluorescence signal in the EPM for all dLight-1.1 (top-left) and all GFP (bottom-right) mice. d , Average dLight-1.1 signal during entries to (left) and exits from (right) the open arm (OA, blue) or closed arm as a control (CA, red). Only traces when the mouse did a complete closed arm to center (Ce) to open/closed arm are used for averaging. e , Average area under the curve (AUC) by EPM compartment for dLight-1.1 (left) and GFP (right) mice. LMM-ANOVA: compartment F 2,80 = 49.82 p < 0.0001, sensor F 3,40 = 1.70 p = 0.1822, compartment x sensor F 6,80 = 5.1529 p = 0.0002; followed by FDR-adjusted post-hoc tests. f , Experimental schematic for slice electrophysiological recordings from vCA1/vSub D1 or D2 pyramidal neurons identified in D1-Cre or D2-Cre x fl/fl eGFP::L10a male mice. g , Representative traces of resting membrane potential before, during and after bath application of dopamine (DA, 10 µM) or of the D1 agonist <t>SKF81297</t> (SKF, 50 µM) onto D1 neurons (top), or of dopamine (DA, 10 µM) or of the D2 agonist quinpirole (Quin, 10 µM) onto D2 neurons (bottom). h , Quantification of resting membrane potential changes between baseline (BL), drug application and after wash (W). LMM-ANOVA: cell type F 1,5.8 = 0.90 p = 0.3805, agonist F 1,18.7 = 0.40 p = 0.5366, application period F 2,37.0 = 17.73 p < 0.0001, cell type x agonist F 1,18.7 = 0.51 p = 0.4851, cell type x application period F 2,37.0 = 16.39 p < 0.0001, agonist x application period F 2,37.0 = 0.23 p = 0.7972, cell type x agonist x application period F 2,37.0 = 0.02 p = 0.9821; followed by FDR-adjusted post-hoc tests. Data represented as mean ± sem.
Skf 81297, supplied by Microm International GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/skf+81297/skf+81297/pmc01160727-17-11-18
Average 90 stars, based on 1 article reviews
skf 81297 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
skf 81297  (Hello Bio Inc)
86
Hello Bio Inc skf 81297
a , Experimental schematic. Male mice were injected in vSub with an AAV-dLight-1.1 (n = 15), an AAV-GRAB DA -1h (n = 15, ), an AAV-RdLight-1 (n = 6, ) or with a control AAV-GFP (n = 8) and implanted with optical fibers before recording during EPM testing. b , Representative traces during EPM exploration for a dLight-1.1 (top) and control GFP (bottom) animal. c , Spatially averaged fluorescence signal in the EPM for all dLight-1.1 (top-left) and all GFP (bottom-right) mice. d , Average dLight-1.1 signal during entries to (left) and exits from (right) the open arm (OA, blue) or closed arm as a control (CA, red). Only traces when the mouse did a complete closed arm to center (Ce) to open/closed arm are used for averaging. e , Average area under the curve (AUC) by EPM compartment for dLight-1.1 (left) and GFP (right) mice. LMM-ANOVA: compartment F 2,80 = 49.82 p < 0.0001, sensor F 3,40 = 1.70 p = 0.1822, compartment x sensor F 6,80 = 5.1529 p = 0.0002; followed by FDR-adjusted post-hoc tests. f , Experimental schematic for slice electrophysiological recordings from vCA1/vSub D1 or D2 pyramidal neurons identified in D1-Cre or D2-Cre x fl/fl eGFP::L10a male mice. g , Representative traces of resting membrane potential before, during and after bath application of dopamine (DA, 10 µM) or of the D1 agonist <t>SKF81297</t> (SKF, 50 µM) onto D1 neurons (top), or of dopamine (DA, 10 µM) or of the D2 agonist quinpirole (Quin, 10 µM) onto D2 neurons (bottom). h , Quantification of resting membrane potential changes between baseline (BL), drug application and after wash (W). LMM-ANOVA: cell type F 1,5.8 = 0.90 p = 0.3805, agonist F 1,18.7 = 0.40 p = 0.5366, application period F 2,37.0 = 17.73 p < 0.0001, cell type x agonist F 1,18.7 = 0.51 p = 0.4851, cell type x application period F 2,37.0 = 16.39 p < 0.0001, agonist x application period F 2,37.0 = 0.23 p = 0.7972, cell type x agonist x application period F 2,37.0 = 0.02 p = 0.9821; followed by FDR-adjusted post-hoc tests. Data represented as mean ± sem.
Skf 81297, supplied by Hello Bio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/skf+81297/81297+skf/pmc06880649-410-3-4
Average 86 stars, based on 1 article reviews
skf 81297 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
agonist skf 81297  (Dawley Inc)
86
Dawley Inc agonist skf 81297
a , Experimental schematic. Male mice were injected in vSub with an AAV-dLight-1.1 (n = 15), an AAV-GRAB DA -1h (n = 15, ), an AAV-RdLight-1 (n = 6, ) or with a control AAV-GFP (n = 8) and implanted with optical fibers before recording during EPM testing. b , Representative traces during EPM exploration for a dLight-1.1 (top) and control GFP (bottom) animal. c , Spatially averaged fluorescence signal in the EPM for all dLight-1.1 (top-left) and all GFP (bottom-right) mice. d , Average dLight-1.1 signal during entries to (left) and exits from (right) the open arm (OA, blue) or closed arm as a control (CA, red). Only traces when the mouse did a complete closed arm to center (Ce) to open/closed arm are used for averaging. e , Average area under the curve (AUC) by EPM compartment for dLight-1.1 (left) and GFP (right) mice. LMM-ANOVA: compartment F 2,80 = 49.82 p < 0.0001, sensor F 3,40 = 1.70 p = 0.1822, compartment x sensor F 6,80 = 5.1529 p = 0.0002; followed by FDR-adjusted post-hoc tests. f , Experimental schematic for slice electrophysiological recordings from vCA1/vSub D1 or D2 pyramidal neurons identified in D1-Cre or D2-Cre x fl/fl eGFP::L10a male mice. g , Representative traces of resting membrane potential before, during and after bath application of dopamine (DA, 10 µM) or of the D1 agonist <t>SKF81297</t> (SKF, 50 µM) onto D1 neurons (top), or of dopamine (DA, 10 µM) or of the D2 agonist quinpirole (Quin, 10 µM) onto D2 neurons (bottom). h , Quantification of resting membrane potential changes between baseline (BL), drug application and after wash (W). LMM-ANOVA: cell type F 1,5.8 = 0.90 p = 0.3805, agonist F 1,18.7 = 0.40 p = 0.5366, application period F 2,37.0 = 17.73 p < 0.0001, cell type x agonist F 1,18.7 = 0.51 p = 0.4851, cell type x application period F 2,37.0 = 16.39 p < 0.0001, agonist x application period F 2,37.0 = 0.23 p = 0.7972, cell type x agonist x application period F 2,37.0 = 0.02 p = 0.9821; followed by FDR-adjusted post-hoc tests. Data represented as mean ± sem.
Agonist Skf 81297, supplied by Dawley Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/skf+81297/81297+agonist+skf/10__1016_slash_s0376___8716_ascii40_00_ascii41_90000___0-608-17-4
Average 86 stars, based on 1 article reviews
agonist skf 81297 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
skf 81297 hydrobromide  (Biosynth Carbosynth)
N/A
D1-like dopamine receptor agonist. D1-like dopamine receptor agonist.
   Buy from Supplier
(r)-skf-81297 hydrobromide  (TargetMol)
N/A
   Buy from Supplier
r(+)-skf-81297 hydrobromide  (Aladdin Scientific Corporation)
N/A
A selective D1 dopamine receptor agonist.
   Buy from Supplier

Image Search Results


a , Experimental schematic. Male mice were injected in vSub with an AAV-dLight-1.1 (n = 15), an AAV-GRAB DA -1h (n = 15, ), an AAV-RdLight-1 (n = 6, ) or with a control AAV-GFP (n = 8) and implanted with optical fibers before recording during EPM testing. b , Representative traces during EPM exploration for a dLight-1.1 (top) and control GFP (bottom) animal. c , Spatially averaged fluorescence signal in the EPM for all dLight-1.1 (top-left) and all GFP (bottom-right) mice. d , Average dLight-1.1 signal during entries to (left) and exits from (right) the open arm (OA, blue) or closed arm as a control (CA, red). Only traces when the mouse did a complete closed arm to center (Ce) to open/closed arm are used for averaging. e , Average area under the curve (AUC) by EPM compartment for dLight-1.1 (left) and GFP (right) mice. LMM-ANOVA: compartment F 2,80 = 49.82 p < 0.0001, sensor F 3,40 = 1.70 p = 0.1822, compartment x sensor F 6,80 = 5.1529 p = 0.0002; followed by FDR-adjusted post-hoc tests. f , Experimental schematic for slice electrophysiological recordings from vCA1/vSub D1 or D2 pyramidal neurons identified in D1-Cre or D2-Cre x fl/fl eGFP::L10a male mice. g , Representative traces of resting membrane potential before, during and after bath application of dopamine (DA, 10 µM) or of the D1 agonist SKF81297 (SKF, 50 µM) onto D1 neurons (top), or of dopamine (DA, 10 µM) or of the D2 agonist quinpirole (Quin, 10 µM) onto D2 neurons (bottom). h , Quantification of resting membrane potential changes between baseline (BL), drug application and after wash (W). LMM-ANOVA: cell type F 1,5.8 = 0.90 p = 0.3805, agonist F 1,18.7 = 0.40 p = 0.5366, application period F 2,37.0 = 17.73 p < 0.0001, cell type x agonist F 1,18.7 = 0.51 p = 0.4851, cell type x application period F 2,37.0 = 16.39 p < 0.0001, agonist x application period F 2,37.0 = 0.23 p = 0.7972, cell type x agonist x application period F 2,37.0 = 0.02 p = 0.9821; followed by FDR-adjusted post-hoc tests. Data represented as mean ± sem.

Journal: bioRxiv

Article Title: Dopaminoceptive D1 and D2 neurons in ventral hippocampus arbitrate approach and avoidance in anxiety

doi: 10.1101/2023.07.25.550554

Figure Lengend Snippet: a , Experimental schematic. Male mice were injected in vSub with an AAV-dLight-1.1 (n = 15), an AAV-GRAB DA -1h (n = 15, ), an AAV-RdLight-1 (n = 6, ) or with a control AAV-GFP (n = 8) and implanted with optical fibers before recording during EPM testing. b , Representative traces during EPM exploration for a dLight-1.1 (top) and control GFP (bottom) animal. c , Spatially averaged fluorescence signal in the EPM for all dLight-1.1 (top-left) and all GFP (bottom-right) mice. d , Average dLight-1.1 signal during entries to (left) and exits from (right) the open arm (OA, blue) or closed arm as a control (CA, red). Only traces when the mouse did a complete closed arm to center (Ce) to open/closed arm are used for averaging. e , Average area under the curve (AUC) by EPM compartment for dLight-1.1 (left) and GFP (right) mice. LMM-ANOVA: compartment F 2,80 = 49.82 p < 0.0001, sensor F 3,40 = 1.70 p = 0.1822, compartment x sensor F 6,80 = 5.1529 p = 0.0002; followed by FDR-adjusted post-hoc tests. f , Experimental schematic for slice electrophysiological recordings from vCA1/vSub D1 or D2 pyramidal neurons identified in D1-Cre or D2-Cre x fl/fl eGFP::L10a male mice. g , Representative traces of resting membrane potential before, during and after bath application of dopamine (DA, 10 µM) or of the D1 agonist SKF81297 (SKF, 50 µM) onto D1 neurons (top), or of dopamine (DA, 10 µM) or of the D2 agonist quinpirole (Quin, 10 µM) onto D2 neurons (bottom). h , Quantification of resting membrane potential changes between baseline (BL), drug application and after wash (W). LMM-ANOVA: cell type F 1,5.8 = 0.90 p = 0.3805, agonist F 1,18.7 = 0.40 p = 0.5366, application period F 2,37.0 = 17.73 p < 0.0001, cell type x agonist F 1,18.7 = 0.51 p = 0.4851, cell type x application period F 2,37.0 = 16.39 p < 0.0001, agonist x application period F 2,37.0 = 0.23 p = 0.7972, cell type x agonist x application period F 2,37.0 = 0.02 p = 0.9821; followed by FDR-adjusted post-hoc tests. Data represented as mean ± sem.

Article Snippet: Dopamine hydrochloride (Tocris, #3548), SKF81297 hydrobromide (Tocris, #1447) and (-)-Quinpirole hydrochloride (Tocris, #1061) were diluted in ACSF (see below) to respectively 10, 50 and 10 μM, extemporaneously for each day of recording, and kept protected from light for the duration of the bath perfusion.

Techniques: Injection, Control, Fluorescence, Membrane